At this year’s congress of the European Association of Dermato-Oncology (EADO), current recommendations for the management of cutaneous squamous cell carcinoma (cSCC) were outlined. The first-line therapy remains complete excision with histologic incision margin control. Adjuvant radiotherapy may be considered depending on the risk of recurrence. In advanced non-resectable cSCC, immune checkpoint inhibition is considered first-line therapy. Chemotherapeutic agents or EGFR inhibitors may be used if contraindications exist. Follow-up should be risk-adapted and include lymph node ultrasonography in high-risk patients.
This content is machine-translated. Please contact us if you need professional translation services.
Publikation
- DERMATOLOGIE PRAXIS
Related Topics
You May Also Like
- Cardiac arrhythmias
Atrial fibrillation – what do current guidelines say?
- PANCREATIC CELLS
Exploration map
- DIABETES AND OBESITY
Influence of movement and muscle regulation
- New studies on COPD
From inhalers, allergies and physical activity
- Rare diseases
The Alagille syndrome
- The future is near or here?
Ablation for atrial fibrillation
- Interventional valve therapy
Gender differences
- Anemia